NCT00004642View on ClinicalTrials.gov

Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 1995

Conditions
Cytomegalovirus Infections
Interventions
DRUG

SDZ MSL-109

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

National Center for Research Resources (NCRR)

NIH